These findings suggest that PPAR-γ full agonists could be therapeutically effective against cystic disease progression in PKD patients, although higher risk of bladder cancer with the use of pioglitazone or rosiglitazone is a concern [17], [18], [19]. The gene discussed is PPARG; the disease is urinary bladder cancer.